Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age40+
SponsorFirst Affiliated Hospital of Wannan Medical College
About this trial
This study is a multicenter, double-blind, placebo-controlled, randomized clinical trial that aims to evaluate the efficacy of probucol on the reduction of the risk of recurrent stroke in patients with symptomatic intracranial or extracranial arterial stenosis.
Eligibility criteria
Qualifiers
None
Disqualifiers
Presumed cardiac source of embolus, such as atrial fibrillation, prosthetic cardiac valve, endocarditis or patent foramen ovale;
Stroke/TIA due to arterial dissection, angioplasty, or vascular surgery;
Usage of probucol within 30 days before randomization;
Known allergy or sensitivity or intolerance to probucol;
Trial design
Treatments tested in this trial
- Probucol
- Placebo probucol
Treatment groups
5,452 Participants
are divided into 2 treatment groupsSponsors and collaborators
First Affiliated Hospital of Wannan Medical College
Lead sponsor
Beijing Tiantan Hospital
Collaborator
Source ClinicalTrials.gov